Objective: To estimate caffeine PK in premature infants during a clinical evaluation of sterile caffeine citrate (CC) for prevention of AOP.
Methods: A NONMEM analyses was applied to caffeine plasma measurements obtained during an oral/iv regimen of CC; 10 mg/kg caffeine base load followed by a daily maintenance dose of 2.5 mg/kg [double-blind (DB) caffeine phase] or 10 mg/kg load followed by daily maintenance dose of 3 mg/kg[open-label (OL) caffeine phase].
Results: A total of 58 (36 male/22 female) subjects with AOP were examined (DB, n=43 and OL, n=15); mean ± SD gestational age, postconceptual age at study onset, and weight were 30 ± 2 weeks, 31± 1 weeks, and 1,228 ± 240 grams. Subjects race were caucasian(n=21), black american (n=10), oriental (n=2), hispanic (n=22), and other(n=3). Baseline apnea episodes/day prior to CC therapy were grouped: < 8(n=22); 8 - 13 (n=25); ≥ 14 (n=11). The best fit model assumed clearance(Cl) and volume of distribution (Vd) to be proportional to weight: Cl = 4.39 ml/kg·hr (CV = 37%); Vd = 0.834 L/kg (CV = 22%).
Conclusions: PK data support weight-adjusted loading and maintenance dosing. Cl may be higher in infants with increased apnea episodes and hispanics may have a larger Vd.
Author information
Authors and Affiliations
Consortia
Additional information
(Spon by: Richard D Leff) Funded by O.P.R. Development, L.P.
Rights and permissions
About this article
Cite this article
Leff, R., Erenberg, A., Wynne, B. et al. Caffeine Pharmacokinetics (PK) In Premature Infants With Apnea of Prematurity(AOP) 340. Pediatr Res 43 (Suppl 4), 60 (1998). https://doi.org/10.1203/00006450-199804001-00361
Issue Date:
DOI: https://doi.org/10.1203/00006450-199804001-00361